Bioanalytical Testing Services Market Report 2025

The bioanalytical testing services market size has grown strongly in recent years. It will grow from $3.45 billion in 2024 to $3.71 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to mobility and transportation changes, environmental considerations, cultural and social trends, competition and industry growth, innovations in design and creativity.

The bioanalytical testing services market size is expected to see rapid growth in the next few years. It will grow to $5.61 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to digital transformation, targeted advertising solutions, mobile integration, augmented reality (AR) and virtual reality (VR), environmental sustainability. Major trends in the forecast period include cross-channel campaigns, interactive advertising, mobile integration, data-driven targeting, programmatic buying.

The increasing government initiatives to control infectious disease outbreaks are significantly driving the growth of the bioanalytical testing services market. The COVID-19 pandemic has heightened demand for these services, prompting countries worldwide to enhance efforts and increase funding to prevent the spread and impact of diseases. For example, in March 2023, a report from the Congressional Research Service, a U.S.-based public policy research institute, indicated that funding from the National Institutes of Health (NIH) for Allergy and Infectious Diseases (NIAID) rose from $6.32 billion to $6.56 billion in 2023. Therefore, the growing government initiatives aimed at managing infectious disease outbreaks are fueling the bioanalytical testing services market.

The escalating prevalence of chronic diseases is anticipated to drive the growth of the bioanalytical testing services market in the foreseeable future. Chronic diseases, characterized by enduring illness lasting three months or more and with the potential to worsen over time, necessitate effective diagnostic and monitoring tools. Bioanalytical testing services play a crucial role in identifying and measuring specific biomarkers associated with chronic diseases, aiding in therapeutic drug monitoring to ensure optimal drug levels within the therapeutic range. As an example, the National Library of Medicine reported in January 2023 that the number of individuals in the US aged 50 and older with at least one chronic condition is projected to increase by 99.5%, reaching 142.66 million by 2050. Furthermore, according to the World Health Organization's 2022 Highlights in September 2022, 74% of all global deaths, amounting to 41 million annually, result from noncommunicable diseases (NCDs) or chronic diseases. This surge in chronic diseases' prevalence is a key driver propelling the growth of the bioanalytical testing services market.

Major companies within the bioanalytical testing services market are actively pursuing advanced solutions, exemplified by the introduction of technologies such as reverse transcription PCR (RT-PCR) tests, to fortify their market positions. RT-PCR is a laboratory technique involving the conversion of RNA into complementary DNA (cDNA) using the reverse transcriptase enzyme. A case in point is Eurofins Scientific SE, a France-based testing laboratory company, which, in June 2023, launched the NovaType SARS-CoV-2 RT-PCR assay. This clinically validated assay offers a short turnaround time, making it well-suited for the re-testing of millions of positive samples to identify specific virus variants. The NovaType SARS-CoV-2 RT-PCR assay, functioning in real-time, is designed for the qualitative detection of SARS-CoV-2, the virus responsible for COVID-19, and the subsequent identification of specific variants, including B.1.1.7 and B.1.351. This strategic focus on advanced solutions underscores the commitment of major companies to staying at the forefront of technological advancements in the bioanalytical testing services market.

Major companies in the bioanalytical testing services market are concentrating on developing testing facilities to maintain their competitive edge. These facilities are specialized environments designed and equipped to perform various tests on products, materials, systems, or components. For instance, in August 2024, SGS S.A., a Switzerland-based inspection, verification, testing, and certification service provider, launched new specialized bioanalytical testing services at its facility in Hudson, New Hampshire. This initiative aims to enhance support for various stages of drug development, particularly focusing on discovery, pre-clinical, and clinical trials from phases 1 to 3. The newly introduced services include method transfer, validation, pharmacokinetics (PK) bioanalysis, immunogenicity testing, and a variety of bioassays.

In February 2022, Eurofins Scientific, a France-based laboratory service company, announced the acquisition of Genetic Testing Service JSC for an undisclosed amount. This strategic move is expected to facilitate Eurofins' expansion in the clinical genetic testing market and complement its global network of clinical diagnostics laboratories. Genetic Testing Service JSC, based in Vietnam, is a company specializing in genetic testing services, including specialized DNA testing, genealogical DNA tests, and testing for conditions such as cancer and COVID-19.

Major companies operating in the bioanalytical testing services market include CD BioSciences, Thermo Fisher Scientific Inc., Merck KGaA, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, ICON plc, PPD Inc., SGS SA, WuXi AppTec, Syneos Health Inc., Sartorius AG, Charles River Laboratories Inc., Intertek Group, Covance Inc., PAREXEL International Corporation, Element Materials Technology, ALS Limited, Medpace Holdings Inc., Almac Group, Pace Analytical Services LLC, Altasciences, BioAgilytix Labs, Frontage Laboratories Inc., Cinven Ltd. (LGC Limited), Toxikon Inc., Absorption Systems LLC, Lotus Labs Pvt. Ltd., Bioneeds India Private Limited, Vipragen Biosciences Pvt. Ltd., Source BioScience.

North America was the largest region in the bioanalytical testing services market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioanalytical testing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioanalytical testing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bioanalytical testing services encompass cutting-edge methodologies for quantifying analytes. These services play a pivotal role in identifying and characterizing pharmaceuticals and metabolites within biological fluids such as blood, plasma, serum, urine, or tissue extracts.

Bioanalytical testing services encompass various essential tests, including ADME (absorption, distribution, metabolism, and excretion), pharmacokinetic, pharmacodynamic, bioequivalence, and bioavailability assessments. ADME examines how a chemical undergoes absorption, distribution, metabolism, and excretion within a living organism, crucial for understanding drug processing. It aids in evaluating safety, toxicity, and the viability of drugs, offering precise targets for future research and development endeavors. These testing services analyze both small and large molecules, catering to pharmaceutical and biopharmaceutical companies, contract development and manufacturing organizations, as well as contract research organizations. They serve as indispensable tools in drug development and assessment, providing vital insights into a compound's behavior within biological systems.

The bioanalytical testing services market research report is one of a series of new reports that provides bioanalytical testing services market statistics, including bioanalytical testing services industry global market size, regional shares, competitors with a bioanalytical testing services market share, detailed bioanalytical testing services market segments, market trends and opportunities, and any further data you may need to thrive in the bioanalytical testing services industry. This bioanalytical testing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bioanalytical testing services market includes revenues earned by entities by providing services such as method development, high throughput sample analysis, method validation, and pharmacokinetic and toxicokinetic support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.